-+ 0.00%
-+ 0.00%
-+ 0.00%

Inovio Pharmaceuticals (INO) Stock Offers No Clear Value Read After 110% Jump

Simply Wall St·11/21/2026 04:21:50
Listen to the news

Inovio Pharmaceuticals has seen its share price move sharply in recent weeks, which puts fresh attention on a simple question for you as an investor: Is the current market value of the stock still in line with what its balance sheet and book value suggest the business is worth?

  • The stock has returned about 109.8% over the past month, which puts a lot more weight on whether the underlying equity on Inovio Pharmaceuticals' balance sheet can support that kind of price shift.
  • The recent FDA accelerated approval of VOCERYQ and the planned commercial launch, backed by a US$80.5 million capital raise, may support expectations for future revenue and could also reshape how investors think about the relationship between the share price and the firm's book value over time.
  • The analysts covering Inovio Pharmaceuticals have run their own numbers. See what analysts think Inovio Pharmaceuticals's shares could be worth.

The stock's next move may depend on whether the recent price level looks aligned with Inovio Pharmaceuticals' book value once you set the headlines aside and focus on the balance sheet.

If you want a yardstick for Inovio Pharmaceuticals' sharp 109.8% one month move against other balance sheet focused ideas, it can help to scan solid balance sheet and fundamentals stocks screener (24 results).

Putting Inovio Pharmaceuticals in Context on Book Value

P/B tends to matter most for asset strength and financial cushion, which fits a business like Inovio Pharmaceuticals where the balance sheet is front and center for many investors. The P/B ratio currently sits at 9.7x, and because reported equity is negative, that figure flips to a mathematically negative multiple rather than a clean valuation signal. With no positive book value anchoring the calculation, the ratio stops telling you whether the share price is high or low relative to the accounting capital in the business.

The FDA accelerated approval of VOCERYQ may change how you weigh future prospects, yet it does not fix the fact that P/B breaks down when shareholder equity runs below zero. For anyone assessing Inovio Pharmaceuticals today, that means the recent share price move needs to be judged against cash runway, future funding needs and the quality of upcoming cash flows instead of relying on this single headline multiple. With this multiple ruled out, take a closer look at what Inovio Pharmaceuticals's balance sheet and debt position show instead.

NasdaqCM:INO P/B Ratio as at Nov 2026
NasdaqCM:INO P/B Ratio as at Nov 2026

The Inovio Pharmaceuticals Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Inovio Pharmaceuticals' valuation puzzle leaves off. They spell out which paths for growth, profitability and earnings would need to hold for the share price to look meaningfully higher or lower than it does today. Each scenario links its number to a clear view on how Inovio Pharmaceuticals' revenue potential, margin profile and risk mix might evolve, giving you a reference point you can return to as fresh information comes through.

One of the top narratives on Inovio Pharmaceuticals: 72% undervalued

This Narrative is the analyst consensus Narrative on Simply Wall St, which compiles analysts' consensus price target and revenue and earnings forecasts, not one person's view.

"Disciplined expense management, shown by a reported more than 20% year over year reduction in operating costs while advancing 3107 toward launch, sets a lean operating base..."

Discover why this Narrative puts Inovio Pharmaceuticals at 72% undervalued.

The share price is only one piece of the Inovio Pharmaceuticals puzzle

Balance sheet metrics and recent headlines only tell part of the story for Inovio Pharmaceuticals, because analyst models sketch out where they expect this business to be a few years from now and give you a different reference point to compare with today's price. Explore where analysts expect Inovio Pharmaceuticals to be in a few years.